Adult T-cell leukemia/lymphoma triggered by adalimumab

J Clin Virol. 2013 Oct;58(2):494-6. doi: 10.1016/j.jcv.2013.07.011. Epub 2013 Aug 1.

Abstract

Here, we describe a 48-year-old woman infected by the human T-cell lymphotropic virus type 1 (HTLV-1) with spondyloarthritis, uveitis, bilateral episcleritis and neurogenic bladder. She had a history of a probable infective dermatitis associated with HTLV-1 (IDH) in childhood. After the use of adalimumab, she developed lymphocytosis and a cutaneous lymphoma associated with IDH. She had the diagnoses of IDH and of chronic adult T-cell leukemia/lymphoma, supported by the demonstration of proviral integration in the cutaneous lesion.

Keywords: Adalimumab; Adult T-cell leukemia/lymphoma; Anti-TNF-α drugs; Infective dermatitis associated with HTLV-1.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adalimumab
  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Female
  • Human T-lymphotropic virus 1 / isolation & purification*
  • Humans
  • Immunologic Factors / administration & dosage*
  • Immunologic Factors / adverse effects*
  • Leukemia-Lymphoma, Adult T-Cell / chemically induced*
  • Middle Aged

Substances

  • Antibodies, Monoclonal, Humanized
  • Immunologic Factors
  • Adalimumab